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on these evaluations. Nephrologists do not need to know how
these steps are met, but they do need to know how to
collaborate with non-clinical experts, such as psychologists,
to develop effective information interventions; psychologists’
expertise is in understanding how people think and behave.
Finkelstein’s paper proposes a challenge for nephrologists to
enhance the education of their patients. The challenge,
however, may be to develop a willingness on nephrologists’
part to be educated by expert non-clinicians.
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The letter by Mooney et al.1 concerning our article2
emphasizes the challenges facing nephrologists in terms of
providing education for patients with chronic kidney
disease (CKD). His points are indeed very well taken.
There needs to be a complete re-examination of how
education is provided to CKD patients. Psychologists and
educators need to be recruited to assist in the development
of these education programs. Clinical staff, including
nephrologists, nurses, dieticians, social workers, and
clerical personnel, need to be recruited to learn more
effective communication skills to provide education to
patients of varying educational and ethnic backgrounds.
As pointed out by Mooney et al., the ‘science underpinning
patients’ behavior and decision making’ needs to be
critically studied and examined in the context of patient
outcomes and perceived knowledge. These challenges are
made all the more difficult because of the complex medical
problems of the patients and the particular challenges
presented in dealing with the cognitive and psychosocial
problems of CKD patients.
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To the Editor: I read the interesting article by Schileper et al.1
The authors stated that the vascular access calcification can
predict mortality among dialysis patients. In Table 4 of this
article, the authors described how age, high-sensitive
C-reactive protein, carotid intima media thickness, and
iliacal calcification were significant predictors for mortality
by a univariate Cox regression model. However, in Table 3 of
this article, they reported multivariate Cox regression results
by adjusting for age, diabetes mellitus, dialysis vintage, Kt/V,
and presence of vascular disease by entry method.
I don’t agree with their ignoring those significant
predictors of mortality by using the entry method because
carotid intima media thickness, iliacal calcification, and
C-reactive protein were reported to be associated with
patients’ mortality.2–4 If they adjusted these three factors by
forward or backward methods in a Cox regression model,5
the results are likely to have been significantly different. The
vascular access calcification might have been non-significant
in this model. If this happened, the vascular access
calcification would have been called an intermediate factor
from the point of view of epidemiology.
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We thank Dr Lin for the letter to our article.
In our article,1 we gave the first systematic overview
of vascular access calcification and described risk
factors for the development of vascular access calcification
such as male gender, diabetes mellitus, and dialysis
vintage. Moreover, we found that the presence of vascular
access calcification is related to an increased mortality risk,
even after adjustment for these and other important
confounders. Therefore, the detection of vascular access
calcification represents a cost-effective and easy-to-
perform method to identify patients at increased
mortality risk.
As pointed out by Dr Lin, not only vascular access,
calcification, but also high-sensitive C-reactive protein,
carotid intima media thickness, and iliacal/femoral
calcification were related to increased mortality in our
study (Table 4 of original article1), and therefore could be
potential confounding factors on the predictive value of
vascular access calcification on mortality. In addition, we
performed a stepwise Cox regression analysis with the
above-mentioned potential confounders plus age (Table 1).
In this model we found that, even after adjustment of these
confounders, the presence of vascular access calcification
was associated with an approximately twofold mortality
risk (ranging from 1.77 to 2.60).
Taken together, the presence of vascular access calcifica-
tion is an important predictor of mortality in dialysis
patients.
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To the Editor: Reich et al.1 investigated the angiotensin-
converting enzyme 2 (ACE2) gene and protein expression in
patients with diabetic nephropathy. The authors seem to
interchangeably use kidneys in patients with diabetes and
diabetic patients with kidney disease (i.e., diabetic nephro-
pathy), which are two different diagnoses. For example, ‘The
strengths of the current study are that we compared ACE2
and ACE expression in the kidney of subjects with type 2 DM
with the kidneys of healthy control subjectsy’1 seems to
conflict with the study by Tikellis et al.,2 which reported
ACE2 expression in rats with streptozocin-induced diabetes
after 24 weeks. The different glomerular expression of ACE2
in these two studies may not be a conflicting report but a
report of ACE2 expression in two separate cohorts. This
raises two questions: (1) Is there a difference in ACE2 gene
and protein expression between patients with diabetes
without nephropathy and diabetic patients with nephro-
pathy? and (2) is there a specific pattern of expression that
may predict future development of nephropathy in diabetic
patients without nephropathy?
Also, Parving et al.3 reported the antiproteinuric effect of
the renin inhibitor, aliskiren (in combination with Losartan)
in patients with diabetic nephropathy. As ACE2 activity is
dependent on production of angiotensin peptides from
angiotensin I and II, and angiotensin I is produced by the
action of renin on angiotensinogen, the use of renin
inhibitors will decrease production of angiotensin I as well
as angiotensin peptides 1–7 and 1–9. It would be interesting
to know what the long-term effect of rennin inhibitors will
be. The use of renin inhibitors may reduce or eliminate the
beneficial effect of the ACE2 pathway.
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Table 1 | Effect of vascular access calcification on total
mortality determined by stepwise Cox regression analysis
Model HR 95% CI P-value
Step 1 Vascular access calcification 2.14 1.11–4.12 0.023
Step 2 Step 1 + gender 2.29 1.15–4.55 0.018
Step 3 Step 2 + diabetes mellitus 2.24 1.12–4.49 0.023
Step 4 Step 3 + dialysis vintage 2.60 1.25–5.40 0.010
Step 4 + iliacal/femoral calcification 2.39 1.14–4.99 0.021
Step 4 + CRP 2.27 1.08–4.80 0.032
Step 4 + IMT 1.99 0.87–4.53 0.103
Step 5 Step 4 + age 2.53 1.24–5.15 0.010
Step 6 Step 5 + iliacal/femoral calcification 2.38 1.16–4.90 0.018
Step 7 Step 6 + CRP 2.02 0.94–4.34 0.070
Step 7 + IMT 1.77 0.77–4.05 0.180
CRP, high sensitive C-reactive protein (mg/l); 95% CI, 95% confidence interval; HR,
hazard ratio; IMT, carotid intima-media thickness (mm).
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